Fifty-four subjects were studied: 36 advanced prostatic adenocarcinoma patients in stage D and 18 normal age-matched male controls. Serum alkaline phosphatase, serum acid phosphatase, plasma osteocalcin, 24-h urinary hydroxyproline excretion, and 24-h whole-body retention of [99mTc]-methylene diphosphonate were measured in all subjects before and 3, 6, and 9 weeks after the start of treatment. Skeletal metastases were identified by radiography and/or [99mTc]-methylene diphosphonate bone scan. The results confirm that acid phosphatase is a significant marker in prostatic cancer; serum alkaline phosphatase may be useful in the evaluation and monitoring of bone metastases but it is not always specific; urinary excretion of hydroxyproline is an index of osteoclastic activity; serum osteocalcin may be considered more specific in the evaluation and monitoring of osteoblastic bone metastases in prostatic cancer.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Serum osteocalcin concentration in patients with prostatic cancer.|
|Rivista:||AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS|
|Citazione:||Francini, G., Bigazzi, S., Leone, V., & Gennari, C. (1988). Serum osteocalcin concentration in patients with prostatic cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS, 11(2s), 83-87.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: